The commercial launch of the Aliquot Directional Bone Tamp provides Orthovita with the opportunity to compete in the cavity creation space using a technology that is designed to work with Cortoss.
The Directional Bone Tamp integrates with the existing vertebral body access tools offered with the Aliquot Delivery System to core and displace bone.
Orthovita said gently actuating the stainless steel cutting element of the Directional Bone Tamp creates curvilinear channels that produce pathways to reduce material flow resistance and optimize therapeutic material placement.
Orthovita CEO Antony Koblish said the Aliquot Directional Bone Tamp enhances the material flow benefits of Orthovita’s proprietary bone augmentation material, Cortoss, an injectable, bioactive composite that mimics the mechanical properties of human cortical bone.
"Cortoss is the only alternative to polymethylmethacrylate (PMMA) cement that has been evaluated in a large-scale, multi-center, randomized, controlled clinical study and is cleared in the US for the treatment of vertebral compression fractures," Koblish said.
"The introduction of this device allows Orthovita to more effectively compete in the kyphoplasty segment of the vertebral compression fracture (VCF) market."
